EOM Pharmaceutical Holdings Reports FDA Clearance of an IND for a Clinical Trial in Cachectic Cancer Patients
EOM Pharmaceutical Holdings received FDA clearance for its IND application to conduct a Phase 2a clinical trial of EOM613 in cachectic cancer patients. The open-label study will enroll approximately 20 Stage 4 cancer patients with Karnofsky Performance Scores of 40-80% and assess weight, lean body mass, and quality of life over three months.
Key figures
- Drug Name
- EOM613
- Phase Of Trial
- Phase 2a
- Age range
- 18-80
- Enrollment target
- 20
- Start date estimate
- Q3 2026
- Karnofsky score range
- 40-80%
- Trial duration months
- 3
- Min life expectancy months
- 4
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.